These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 29104025)

  • 41. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.
    Ravelli A; Roviello G; Cretella D; Cavazzoni A; Biondi A; Cappelletti MR; Zanotti L; Ferrero G; Ungari M; Zanconati F; Bottini A; Alfieri R; Petronini PG; Generali D
    Tumour Biol; 2017 Apr; 39(4):1010428317695023. PubMed ID: 28378631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of inflammation in progression of breast cancer: Friend or foe? (Review).
    Allen MD; Jones LJ
    Int J Oncol; 2015 Sep; 47(3):797-805. PubMed ID: 26165857
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.
    Sanchez K; Page D; McArthur HL
    Curr Probl Cancer; 2016; 40(2-4):151-162. PubMed ID: 27855963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New horizons in breast cancer: the promise of immunotherapy.
    de la Cruz-Merino L; Palazón-Carrión N; Henao-Carrasco F; Nogales-Fernández E; Álamo-de la Gala M; Vallejo-Benítez A; Chiesa M; Sánchez-Margalet V;
    Clin Transl Oncol; 2019 Feb; 21(2):117-125. PubMed ID: 29916188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer.
    Criscitiello C; Esposito A; Trapani D; Curigliano G
    Cancer Treat Rev; 2016 Nov; 50():205-207. PubMed ID: 27744144
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
    Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
    Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
    Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
    Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.
    Gingras I; Azim HA; Ignatiadis M; Sotiriou C
    Clin Adv Hematol Oncol; 2015 Jun; 13(6):372-82. PubMed ID: 26352893
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms of immune evasion in breast cancer.
    Bates JP; Derakhshandeh R; Jones L; Webb TJ
    BMC Cancer; 2018 May; 18(1):556. PubMed ID: 29751789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomarkers for glioma immunotherapy: the next generation.
    Sims JS; Ung TH; Neira JA; Canoll P; Bruce JN
    J Neurooncol; 2015 Jul; 123(3):359-72. PubMed ID: 25724916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of putative breast cancer antigens using an integrative platform of genomics-driven immunoproteomics.
    Qendro V; Lundgren DH; Palczewski S; Hegde P; Stevenson C; Perpetua L; Latifi A; Merriman J; Bugos G; Han DK
    Proteomics; 2017 Aug; 17(15-16):. PubMed ID: 28665052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dendritic cell-based vaccines: clinical applications in breast cancer.
    Gelao L; Criscitiello C; Esposito A; De Laurentiis M; Fumagalli L; Locatelli MA; Minchella I; Santangelo M; De Placido S; Goldhirsch A; Curigliano G
    Immunotherapy; 2014; 6(3):349-60. PubMed ID: 24762078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice.
    de Melo Gagliato D; Cortes J; Curigliano G; Loi S; Denkert C; Perez-Garcia J; Holgado E
    Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):527-537. PubMed ID: 29061314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
    Ibrahim EM; Al-Foheidi ME; Al-Mansour MM; Kazkaz GA
    Breast Cancer Res Treat; 2014 Dec; 148(3):467-76. PubMed ID: 25361613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.
    Montagna E; Vingiani A; Maisonneuve P; Cancello G; Contaldo F; Pruneri G; Colleoni M
    Breast; 2017 Aug; 34():83-88. PubMed ID: 28544923
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
    Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
    Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
    Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
    Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.